Issue Date: February 25, 2008
Pfizer Will Acquire Biotech Encysive
Pfizer has agreed to acquire Encysive Pharmaceuticals, a publicly held biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension (PAH) was approved in Europe but has failed to clear U.S. regulators. Pfizer will pay about $195 million for the Houston-based company. Upon completion of the deal, it plans to conduct a Phase III clinical trial to support approval in the U.S. Pfizer already markets Revatio, a PAH treatment discovered in its own labs.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society